REFERENCE
Chouaid C, Monnet I, Robinet G, Perol M, Fournel P, Vergnenegre A.Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Current Medical Research and Opinion 23: 1509-1515, No. 7, Jul 2007
Rights and permissions
About this article
Cite this article
Costs for third-line gefitinib for NSCLC are acceptable. Pharmacoecon. Outcomes News 536, 5 (2007). https://doi.org/10.2165/00151234-200705360-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705360-00014